Biovest International sees a sunnier financial picture for its cancer vaccine hunt, but first that means filing for Chapter 11 and rejiggering its balance sheet.
Writing in Nature Medicine, MD Anderson Cancer Research Center assistant professor Willem Overwijk says he wanted to explore the cancer vaccine strategy to see if he could find the Achilles heel for these new drugs. He ended up with what he called an "aha!" moment when he zeroed in on the ways that investigators equipped vaccines to work.
After taking its big Phase III study of Stimuvax all the way to a conclusive finish, Merck KGaA said the closely-watched lung cancer vaccine failed to demonstrate a significant improvement in overall survival--a flop that will leave a deep scar at Oncothyreon as well, which licensed out the treatment.
The Oregon biotech revealed a pair of agreements focused on the company's therapeutic vaccine for breast cancer, a therapy in Phase III development, including a "signature" pact with the global group Teva Pharmaceutical Industries to commercialize the biotech's lead product in Israel.
PsiOxus Therapeutics nabbed £1.7 million ($2.7 million) from the U.K. government-backed Biomedical Catalyst to start a Phase I/II clinical trial of its cancer vaccine.
This FierceVaccines special report spotlights 10 promising therapeutic vaccines on their way through clinical development that might just change the face of cancer treatment. Many of them are in the early steps of R&D, so it may be a while, especially for those that are first-in-class, or that are bringing a new technology to the table, but they could be the first baby steps to a brave new world.
PsiOxus Therapeutics began human clinical trials of its cancer vaccine ColoAd1--a highly potent anti-cancer therapeutic that destroys tumor cells at minute concentrations.
Dietmar Hopp's investment group, dievini Hopp BioTech Holding, is injecting a whopping $104 million into CureVac, which is preparing new trials for a pair of RNA programs that target prostate cancer and non-small cell lung cancer.
A response between monocyte-derived dendritic cells and cancer has dealt a setback when it comes to fighting the disease with vaccines.
Alnylam Pharmaceuticals and the company's Dutch research partners say they've reached a big milestone using RNAi to drastically boost the potential of a cancer vaccine under development to generate an immune response.